Klaria receives ‘Notice of Allowance’ from the United Stated Patent and Trademark Office (USPTO) for a product patent protecting its most advanced development asset, Sumatriptan Alginate Film
With this approval of a completely new patent, Sumatriptan Alginate Film will enjoy patent-protected market exclusivity in the United States until 2036. This extends the period of market exclusivity in the US by 7 years, thereby increasing the projected cumulative revenue of the product by more than USD 1 billion. Moreover, the breadth of claims in the patent is wide, solidifying the market exclusivity in the patent period. The approval marks the second time the USPTO approves a compound/Alginate Film combination patent that protects an individual compound formulated in Klaria’s proprietary Alginate Film. Thus, the approval validates Klaria’s patent strategy which calls for filing of compound/Alignate Film combination patents for all its development products.
Jesper Wiklund, CEO of Klaria said “7 years of additional patent protection for Sumatriptan Alginate Film equals 7 more years of peak-sales. This is a highly meaningful accomplishment for our company and it significantly increases the value of our most advanced program, with an increase in the projected cumulative sales of the product by more than USD 1 billion. Importantly, the breadth of claims allowed is impressive, which further strengthens our patent position and solidifies the market exclusivity in the patent period until 2036.”
This approval is confirmation of Klaria’s ability to successfully develop unique, patent-protected products that build on the base technology alginate film patents owned by Klaria. Klaria’s intellectual property strategy therefore not only relies on the strength of the ‘base’ technology patent, but also extends the patent life of the individual products through compound/Alginate Film combination patents.
Dr. Scott Boyer, CSO of Klaria added “Today’s news is a confirmation of the technical and intellectual property strategy established by Klaria since its founding. It is also a demonstration of the unique performance of the Alginate Film technology for drug delivery. The granting of this patent is a testament to the diligent, creative and innovative work within our laboratories and among our collaboration partners who have generated the wealth of data on this product that has formed the basis for this patent.”
About Sumatriptan Alginate Film (KL-00119): KL-00119 is an alginate-based oral trans-mucosal film. KL-00119 is the first oral trans-mucosal migraine product and is designed to be a significant improvement to all available acute migraine treatments available to patients today, particularly in patients suffering from migraine-induced nausea and vomiting. KL-00119 is also particularly suited for the treatment of migraine in pediatric populations. KL-00119 is a unique molecular dispersion of the active antimigraine drug sumatriptan. The KL-00119 film presents sumatriptan to the oral mucosal surface in a unique way to allow rapid, consistent absorption with the lowest possible burden on the patient. The base film-forming alginate and the sumatriptan-containing films have been the subject of comprehensive intellectual property protection, thus ensuring prolonged market exclusivity. The uniqueness and promise of the KL-00119 has been confirmed by the project being awarded the exclusive European Commission Horizon 2020 Innovation Grant in 2018 (Grant Number 8296159).
This disclosure contains information that Klaria Pharma Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 21-01-2021 16:27 CET.
For more information, visit the Klaria Pharma Holding website klaria.com or contact:
Jesper Wiklund, CEO Klaria Pharma Holding AB (publ)
Tel: +46 (0) 8-446 42 99
This is Klaria Pharma Holding AB
Klaria (Klaria Pharma Holding AB) is a Swedish listed pharmaceutical company that develops innovative, rapid-acting products. By combining patented technology of a film that attaches to the oral mucosa and well proven pharmaceuticals, the company has developed a drug distribution concept with many benefits and potential uses. Klaria is listed on Nasdaq First North Growth Markets under the short name KLAR. FNCA Sweden is Certified Advisor (firstname.lastname@example.org, +46(0) 8-528 00 399) for Klaria Pharma Holding AB. For more information, see www.klaria.com.